Effect of Rosiglitazone on Osteoclastic Differentiation of RAW264.7 Cells under Estrogen.

doi:10.13701/j.cnki.kqyxyj.2019.05.021

Abstract

Abstract: Objective: To investigate the effect and mechanism of rosiglitazone on osteoclastic differentiation of RAW264.7 cells under estrogen. Methods: The murine macrophage RAW264.7 cells lines were induced by RANKL in the presence or absence of rosiglitazone and/or estrogen for 5 days. The number of osteoclasts was detected by TRAP staining and the expression of osteoclast related genes and transcription factors were detected by qRT-PCR. The effects of rosiglitazone and/or estrogen on cell viability were detected by MTT. Results: Rosiglitazone and estrogen increased cell viability. RANKL induced osteoclast formation and the number of osteoclasts, osteoclast related genes and translation factors increased under rosiglitazone or estrogen stimulation (P<0.05). However, rosiglitazone inhibited osteoclast formation, and osteoclast related genes and translation factors were significantly decreased under estrogen (P<0.05). Conclusion: Rosiglitazone could inhibit osteoclast formation by TRAF6 and NFATc1 under estrogen.

Key words: PPARγ, Rosiglitazone, Estrogen, Osteoclast

HU Ying-ying, HA Shan-shan, ZHU Ning-jing, SONG Ya-ling, WANG Chang-ning. Effect of Rosiglitazone on Osteoclastic Differentiation of RAW264.7 Cells under Estrogen.[J]. Journal of Oral Science Research, 2019, 35(5): 502-506.

References

[1] Wang Q, Yao L, Xu K, et al. Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis [J]. J Cell Mol Med, 2019, 23(1):380-394.
[2] Wei W, Wang X, Yang M, et al. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss [J]. Cell Metab, 2010, 11(6):503-516.
[3] Humphrey MB, Nakamura MC. A comprehensive review of immunoreceptor regulation of osteoclasts [J]. Clin Rev Allergy Immunol, 2016, 51(1):48-58.
[4] Xin Z, Jin C, Chao L, et al. A matrine derivative M54 suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by targeting ribosomal protein S5 [J]. Front Pharmacol, 2018, 9:22.
[5] Reddy MS, Morgan SL. Decreased bone mineral density and periodontal management [J]. Periodontol 2000, 2013, 61(1):195-218.
[6] 杨芳,陈明月,胡英英,等.PPARγ在脂多糖刺激牙周膜细胞中调控NF-κB信号通路的作用研究[J].口腔医学研究,2017,33(7):698-702.
[7] Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT) [J]. Diabetes Care, 2018, 31(5):845-851.
[8] Lazarenko OP, Rzonca SO, Hogue WR, et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone [J]. Endocrinology, 2007, 148(6):2669-2680.
[9] Case N, Thomas J, Xie Z, et al. Mechanical input restrains PPARgamma2 expression and action to preserve mesenchymal stem cell multipotentiality [J]. Bone, 2013, 52(1):454-464.
[10] Koufany M, Chappard D, Netter P, et al. The peroxisome proliferator-activated receptor gamma agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway [J]. Arthritis Rheum, 2013, 65(12):3084-3095.
[11] Qiao W, Wang C, Huang W, et al. Peroxisome proliferator-activated receptor gamma plays dual roles on experimental periodontitis in rats [J]. J Clin Periodontol, 2018, 45(5):514-523.
[12] Yan DJ, Chen ZW. 17beta-estradiol increased the expression of daintain/AIF-1 in RAW264.7 macrophages [J]. Biosci Biotechnol Biochem, 2010, 74(10):2103-2105.
[13] Guo L, Chen K, Yuan J, et al. Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARgamma and APC [J]. J Cell Physiol, 2018, 234(1):581-594.
[14] Chen F, Ouyang Y, Ye T, et al. Estrogen inhibits RANKL-induced osteoclastic differentiation by increasing the expression of TRPV5 channel [J]. J Cell Biochem, 2014, 115(4):651-658.
[15] Schwartz AV, Sellmeyer DE, Vittinghoff E. Thiazolidinedione use and bone loss in older diabetic adults [J]. J Clin Endocrinol Metab, 2006, 91(9):3349-3354.
[16] Nakaya M, Tachibana H, Yamada K. Isoflavone genistein and daidzein up-regulate LPS-induced inducible nitric oxide synthase activity through estrogen receptor pathway in RAW264.7 cells [J]. Biochem Pharmacol, 2005, 71(1-2):108-114.
[17] Wu J, Ru N, Li S. Peroxisome proliferator-activated receptor gamma regulates bone remodeling after midpalatal suture expansion in mice [J]. Int J Oral Maxillofac Implants, 2015, 30(6):1423-1430.
[18] You HJ, Kim JY, Jeong HG. 17β-Estradiol increases inducible nitric oxide synthase expression in macrophages [J]. Biochem Biophys Res Commun, 2003, 303(4):1129-1134.
[19] Powell B, Szleifer I, Dhaher YY. In silico study of principal sex hormone effects on post-injury synovial inflammatory response [J]. PLoS One, 2018, 13(12):e0209582.
[20] Fan P, Abderrahman B, Chai TS, et al. Targeting peroxisome proliferator-activated receptor gamma to increase estrogen-induced apoptosis in estrogen-deprived breast cancer cells [J]. Mol Cancer Ther, 2018, 17(12):2732-2745.
[21] Peng X, Qiao Z, Wang Y, et al. Estrogen reverses nicotine-induced inflammation in chondrocytes via reducing the degradation of ECM [J]. Int J Rheum Dis, 2019, 22(4):666-676.
[22] Yang Y, Zhang N, Lan F, et al. Transforming growth factor-beta 1 pathways in inflammatory airway diseases [J]. Allergy, 2014, 69(6):699-707.
[23] Li Z, Zhang W, Huang Y. MiRNA-133a is involved in the regulation of postmenopausal osteoporosis through promoting osteoclast differentiation [J]. Acta Biochim Biophys Sin (Shanghai), 2018, 50:273-280.
[24] Pi Y, Liang H, Yu Q, et al. Lowfrequency pulsed electromagnetic field inhibits RANK Linduced osteoclastic differentiation in RAW264.7 cells by scavenging reactive oxygen species[J]. Mol Med Rep, 2019, 19(5):4129-4136.
[25] Wang J, Wu X, Duan Y. Magnesium lithospermate B protects against lipopolysaccharide-induced bone loss by inhibiting RANKL/RANK pathway [J]. Front Pharmacol, 2018, 9:64.
[26] Yao Z, Lei W, Duan R, et al. RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors [J]. J Biol Chem, 2017, 292(24):10169-10179.